The European Commission’s Directorate-General for Competition, the Federal Trade Commission (FTC), the Canadian Competition Bureau, the UK Competition and Markets Authority, the US Department of Justice and three US Attorneys General’s offices launched a multilateral working group on Tuesday 16 March to analyse the effects of mergers in the pharmaceutical sector.
The working group was initiated by the FTC and is in line with close cooperation between national competition authorities.